Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Declines By 21.9%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 130,500 shares, a drop of 21.9% from the September 30th total of 167,200 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average daily volume of 73,300 shares, the days-to-cover ratio is presently 1.8 days.

Cyclo Therapeutics Price Performance

CYTH stock opened at $0.75 on Monday. The business has a 50-day moving average price of $0.76 and a 200 day moving average price of $1.09. The company has a market capitalization of $21.32 million, a P/E ratio of -0.75 and a beta of -0.38. Cyclo Therapeutics has a 1-year low of $0.59 and a 1-year high of $2.12.

Cyclo Therapeutics (NASDAQ:CYTH) last released its quarterly earnings data on Thursday, August 15th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.07). The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.40 million. Cyclo Therapeutics had a negative net margin of 1,830.27% and a negative return on equity of 2,741.89%. On average, analysts anticipate that Cyclo Therapeutics will post -0.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on CYTH shares. Ascendiant Capital Markets decreased their target price on Cyclo Therapeutics from $2.60 to $0.95 and set a “buy” rating for the company in a research report on Monday, August 26th. HC Wainwright restated a “neutral” rating and issued a $0.95 price objective (down from $3.00) on shares of Cyclo Therapeutics in a report on Friday, August 23rd. Finally, Maxim Group restated a “hold” rating on shares of Cyclo Therapeutics in a report on Tuesday, August 27th.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.